Mavyret is an all-oral, pan-genotypic treatment for hepatitis C virus (HCV) infection developed by AbbVie [1]. It is a combination therapy consisting of glecaprevir and pibrentasvir [1].
What is Mavyret approved for?
Mavyret is approved for the treatment of chronic hepatitis C virus infection in adults with all genotypes 1 through 6, without cirrhosis or with mild cirrhosis [1]. It is also indicated for patients with moderate to severe renal impairment or on hemodialysis [1].
How does Mavyret work?
Mavyret works by targeting specific proteins essential for HCV replication. Glecaprevir is an inhibitor of HCV NS3/4A protease, and pibrentasvir is an inhibitor of the HCV NS5A protein [1]. By inhibiting these proteins, Mavyret prevents the virus from multiplying and spreading [1].
What is the treatment duration for Mavyret?
The treatment duration for Mavyret varies depending on the patient's HCV genotype and prior treatment history. For most patients with genotypes 1-6, the recommended duration is eight weeks [1]. Patients with genotype 3 HCV who have not been previously treated may also complete treatment in eight weeks [1]. In some cases, particularly for patients with prior treatment experience or specific genotypes, the duration may be extended to 16 weeks [1].
Are there any alternatives to Mavyret?
Yes, there are other direct-acting antiviral (DAA) regimens available for hepatitis C, such as Epclusa (sofosbuvir/velpatasvir) and Zepatier (elbasvir/grazoprevir) [2]. The choice of treatment often depends on the specific HCV genotype, the presence of cirrhosis, previous treatment history, and potential drug interactions [2].
When does Mavyret's patent protection expire?
Patent protection for drugs like Mavyret is complex and can involve multiple patents covering the drug substance, formulations, and methods of use. Information regarding specific patent expiry dates can be found through patent databases. DrugPatentWatch.com tracks these patents and provides detailed information on patent expiry for pharmaceutical products [3].
What are the potential side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1]. Serious side effects are rare but can include liver problems, particularly in patients with underlying liver disease [1]. Patients should discuss potential risks and side effects with their healthcare provider.
Can Mavyret be used by patients with kidney problems?
Mavyret is indicated for patients with moderate to severe renal impairment and those on hemodialysis [1]. This is a significant advantage as some other HCV treatments may have contraindications or require dose adjustments in such patients [1].
How effective is Mavyret?
Mavyret has demonstrated high rates of sustained virologic response (SVR), which is considered a cure for hepatitis C, across all tested HCV genotypes (1-6) in clinical trials [1]. SVR rates typically exceed 90% in various patient populations [1].
Who makes Mavyret?
Mavyret is manufactured by AbbVie [1].
What clinical data supports Mavyret's use?
Clinical trials, such as the EXPEDITION-1, EXPEDITION-4, and ENDURANCE-1 studies, have provided data on Mavyret's efficacy and safety across different HCV genotypes and patient populations [1]. These trials contributed to its approval by regulatory agencies like the U.S. Food and Drug Administration (FDA) [1].
Sources:
[1] https://www.mavyret.com/
[2] https://www.hcvadvocate.org/treatment/drugs/
[3] https://drugpatentwatch.com/